Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 8 · below the Ichimoku cloud · RSI 16 (oversold) · MACD above its signal · at its 52-week low
| 4.58 | 52-week high | +631.75% |
| 2.14 | Previous month high | +241.91% |
| 1.07 | Previous week high | +70.95% |
| 0.9700 | Previous month low | +54.98% |
| 0.7600 | Previous week low | +21.43% |
| 0.7480 | R3 (classic) | +19.51% |
| 0.7270 | R2 (classic) | +16.15% |
| 0.7060 | Previous day high | +12.80% |
| 0.6970 | R1 (classic) | +11.36% |
| 0.6760 | Pivot | +8.00% |
| 0.6550 | Previous day low | +4.65% |
| 0.6460 | S1 (classic) | +3.21% |
| 0.6259 | Price now | |
| 0.6251 | 52-week low | −0.13% |
| 0.6250 | S2 (classic) | −0.14% |
| 0.5950 | S3 (classic) | −4.94% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.2M | 0.00% | 291.04K | +151% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LTRN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 11, 2026 | Keyser Donald Jeffrey Ph.DDirector | Purchase at price 2.06 per share. | 48.5K | $100.00K |
| May 11, 2026 | Schalop Lee TroyDirector | Purchase at price 2.06 per share. | 48.5K | $100.00K |
| Jun 12, 2025 | Kreis Leslie W JrBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.09 per share. | 40K | $123.60K |
| Jun 11, 2025 | Kreis Leslie W JrBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.38 - 3.40 per share. | 61.6K | $208.27K |
| May 28, 2025 | Kreis Leslie W JrBeneficial Owner of more than 10% of a Class of Security | Sale at price 2.87 - 3.05 per share. | 56.2K | $168.42K |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.0 | -10.5 | -51.4 | 49.6 | 75.1 | 16.2 | -36.9 | -22.8 | -50.2 | -38.0 | −79.3% | ||
| 2025 | 55.2 | -20.2 | -10.4 | -0.6 | -13.4 | 3.6 | 40.5 | -8.1 | 6.6 | -7.8 | -9.7 | -16.3 | −5.0% |
| 2024 | -1.4 | 14.0 | 83.0 | -42.0 | 19.0 | -23.1 | -10.1 | -2.6 | -10.3 | -14.9 | 2.7 | -0.6 | −25.5% |
| 2023 | -0.3 | -8.8 | -12.0 | 1.4 | 6.3 | 8.3 | -17.9 | -2.4 | -24.6 | -27.3 | 59.3 | 8.4 | −29.1% |
| 2022 | -16.7 | -7.4 | 16.1 | -16.6 | -2.9 | -1.4 | -10.2 | 0.8 | -7.5 | -12.3 | 19.3 | 20.8 | −24.3% |
| 2021 | -21.9 | 18.2 | 2.1 | -17.3 | 0.7 | -3.4 | -11.6 | 9.2 | -20.7 | -8.7 | -17.3 | -5.5 | −58.5% |
| 2020 | -3.0 | 34.8 | 13.5 | -19.9 | 4.6 | 21.9 | +51.6% |
Buy / hold / sell counts
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.